Exposure to the cannabinoid agonist WIN 55, 212-2 in adolescent rats causes sleep alterations that persist until adulthood

Eur J Pharmacol. 2020 May 5:874:172911. doi: 10.1016/j.ejphar.2020.172911. Epub 2020 Feb 8.

Abstract

Cannabis and, to a lesser extent, synthetic cannabinoids are used during adolescence, a period in which multiple brain areas are still undergoing development. Among such areas is the hypothalamus, which is implicated in the control of sleep-wake cycle. In the present report, we show that exposing adolescent rats to the cannabinoid receptor agonist WIN 55, 212-2 (0.1, 0.3 or 1.0 mg/kg, i.p) for 14 days during adolescence (i.e., from post-natal day 30-44) resulted in significant sleep disturbances when the animals became adult (post-natal day 80). These included decreased wakefulness and enhanced rapid eye movement sleep. Furthermore, we found that labeling for NeuN, a marker of postmitotic neurons, was significantly increased the dorsomedial hypothalamic nucleus of rats treated with WIN 55, 212-2. The results suggest that excessive cannabinoid receptor activation during adolescence can persistently influence sleep patterns and neuronal activity later in life.

Keywords: Adolescence; Cannabinoids; Rapid eye movement sleep; Sleep; WIN 55,212–2.

MeSH terms

  • Animals
  • Antigens, Nuclear / metabolism
  • Benzoxazines / adverse effects*
  • Brain / drug effects
  • Brain / metabolism
  • Cannabinoid Receptor Agonists / adverse effects*
  • Male
  • Morpholines / adverse effects*
  • Naphthalenes / adverse effects*
  • Nerve Tissue Proteins / metabolism
  • Rats, Wistar
  • Sleep / drug effects
  • Sleep Wake Disorders / chemically induced*
  • Sleep Wake Disorders / metabolism

Substances

  • Antigens, Nuclear
  • Benzoxazines
  • Cannabinoid Receptor Agonists
  • Morpholines
  • Naphthalenes
  • Nerve Tissue Proteins
  • Rbfox3 protein, rat
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone